Spiration Valves Against Standard Therapy

NCT ID: NCT02382614

Last Updated: 2024-04-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-31

Study Completion Date

2022-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

VAST is a multicenter, prospective, randomized, controlled study designed to evaluate treatment of persistent air leak with the SVS as compared to standard chest tube drainage management and other standard-of-care interventions in the control group. Eligible subjects will be randomized to receive either Spiration Valves (investigational arm) or continue standard-of-care treatment (control arm). Once the air leak has resolved, Spiration Valves should be removed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Air Leaks

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Spiration Valve System

The treatment group will have valves deployed to achieve leak isolation.

Group Type EXPERIMENTAL

Spiration Valve System

Intervention Type DEVICE

Medical Management

The control group for this study will receive standard chest tube drainage management and standard-of-care interventions. This group will be evaluated and followed in the same manner as the treatment group, but without having valves placed.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spiration Valve System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject has an air leak ≥ 100 mL/min, as measured by a digital thoracic drainage system (DTDS)
* Subject has air leak present on at least the 5th day following origination.

Exclusion Criteria

* Subject has air leak only on forced exhalation or cough
* Subject has sepsis
* Subject has pneumonia
* Subject has Acute Respiratory Distress Syndrome (ARDS)
* Subject is not an appropriate candidate for, or unable to tolerate, flexible bronchoscopy procedures
* Subject has undergone a bone marrow transplant
* Subject has a primary pneumothorax
* Subject has undergone a prior intervention (including pleurodesis, surgery, blood patch, and pneumoperitoneum) or valve placement.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Olympus Corporation of the Americas

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sparks Regional Medical Center

Fort Smith, Arkansas, United States

Site Status

El Camino Hospital

Mountain View, California, United States

Site Status

California Pacific Medical Center

San Francisco, California, United States

Site Status

Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

Southern Illinois University

Springfield, Illinois, United States

Site Status

Olathe Medical Center

Olathe, Kansas, United States

Site Status

University of Maryland

Baltimore, Maryland, United States

Site Status

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status

Lahey Hospital & Medical Center

Burlington, Massachusetts, United States

Site Status

Mayo Clinic Rochester

Rochester, Minnesota, United States

Site Status

Dartmouth Mary Hitchcock Memorial Hospital

Hanover, New Hampshire, United States

Site Status

Cooper University Hospital

Camden, New Jersey, United States

Site Status

The Christ Hospital

Cincinnati, Ohio, United States

Site Status

University of Cincinnati

Cincinnati, Ohio, United States

Site Status

Penn State Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

Temple University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

University of Texas Southwestern

Dallas, Texas, United States

Site Status

Inova Fairfax Hospital

Falls Church, Virginia, United States

Site Status

Swedish Medical Center

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

13

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Validation of Aspiration Markers
NCT02301845 WITHDRAWN PHASE1
The ACES Study for Aseptic Pleural Effusion
NCT06210685 ACTIVE_NOT_RECRUITING NA